In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
26
4
2020
medline:
5
1
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
: Trauma-induced coagulopathy (TIC) occurs commonly as a second event following severe injury. We evaluated the effects of fibrinogen, recombinant factor VIIa and factor XIII on blood clotting and fibrinolysis in an in-vitro TIC model. The TIC model included hemodilution, hyperfibrinolysis, acidosis and hypothermia. The extent of clot formation and fibrinolysis was evaluated using rotational thromboelastometry. Clot strength was increased following spiking the TIC blood with either 1.0 mg/ml fibrinogen, 3.0 μg/ml recombinant factor VIIa or 2.0 IU/ml factor XIII. Maximal effect was achieved by all agents in combination approximating the extent of clot formation to those in normal blood. Fibrinolysis was inhibited by factor XIII, while the reduction was stronger using all agents together. When each of the agents used in two times lower concentrations, clot strength was near to threshold. Fibrinogen and factor XIII but not factor VIIa exerted stimulation of clot strength, whereas synergistic effect of fibrinogen and factor XIII was observed. Maximal effect was achieved combining all agents. The antifibrinolytic effect was observed only by co-administration of fibrinogen, factor XIII and factor VIIa. On the basis of our study, we suggest that stimulation of clot formation and inhibition of fibrinolysis may be achieved by combination of FG, rFVIIa an FXIII using each of them at minimal effective concentration. Taken into consideration, multifactorial TIC pathogenesis, this approach may be preferable for improving coagulopathy than separate blood spiking with the essayed factors at high concentrations.
Identifiants
pubmed: 32332276
doi: 10.1097/MBC.0000000000000910
pii: 00001721-202006000-00003
doi:
Substances chimiques
Fibrinogen
9001-32-5
Factor XIII
9013-56-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-257Références
Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113:1205–1219.
Fries D, Brohi K. The pathophysiology of trauma-induced coagulopathy. Curr Opin Crit Care 2012; 18:631–636.
Duan K, Yu W, Li N. The pathophysiology and management of acute traumatic coagulopathy. Clin Thromb Hemost 2015; 21:645–652.
Levy JH, Szlam E, Tanaka KA, Sniecienski RM. Fibrinogen and haemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114:261–274.
Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10:1342–1351.
Aubron C, Reade MC, Fraser JF, Cooper DJ. Efficacy and safety of fibrinogen concentrate in trauma patients-a systematic review. J Crit Care 2014; 471:e11–e17.
Mengoli C, Franchini M, Marano G, Pupella S, Yaglio S, Marietta M, Liumbruno GM. The use of fibrinogen concentrate for the management of trauma related bleeding: a systematic review and meta-analysis. Blood Transfus 2017; 15:318–324.
Schmidt DE, Halmin M, Wikman A, Ostlund A, Agren A. Relative effects of plasma, fibrinogen concentrate and factor XIII in an in vitro model of massive transfusion in trauma. Scand J Clin Invest 2017; 77:397–405.
Cameron P, Phillips L, Balogh Z, Joseph A, Pearce A, Parr M, Jankelowitz G. The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry. Injury 2007; 38:1030–1038.
Okonta KE, Edwin F, Falase B. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery? Interact Cardiovask Thorac Surg 2012; 15:690–694.
Downey L, Brown ML, Faraoni D, Zurakowski D, DiNardo JA. Recombinant factor VIIa is associated with increased thrombotic complications in pediatric cardiac surgery patients. Anesth Analg 2017; 124:1431–1436.
Stein DM, Dutton BP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008; 39:1054–1061.
Theusinger CM, Baulig W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in rotation thrmboelastometry (ROTEM). Thromb Haemost 2010; 104:385–391.
Nagashima F, Inoue S, Koami H, Sakamoto Y, Kai K. High-dose FXIII administration induces effective hemostasis for trauma associated coagulopathy (TAC) both in vitro and in rat hemorrhagic shock in vivo models. J Trauma Acute Care Surg 2018; 85:588–597.
Zaets SB, Xu DZ, Lu Q, Feketova E, Berezina TL, Malinina IV, Deitch EA, Olsen EH. Recombinant factor XIII mitigates hrmorrhagic shock-induced organ disfunction. J Surg Res 2011; 166:e135–e142.
Shenkman B, Budnik I, Einav Y, Hauschner H, Andreychyn M, Martinowitz U. Model of trauma-induced coagulopathy including hemodilution, fibrinolysis, acidosis, and hypothermia: impact on blood coagulation and platelet function. J Trauma Acute Care Surg 2017; 82:287–292.
Da Luz LT, Nascimento B, Shankarakutty AK, Rizoli S, Adhikari NK. Effect of thromboelastography (TEG) and rotational thromboelastometry (ROTEM) on diagnosis and coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. Crit Care 2014; 18:518.
Veigas PV, Callum J, Rizoli S, Nascimento B, Da Luz LT. A systemic review on the rotation thromboelastometry (ROTEM) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients. Scand J Trauma Resusc Emerg Med 2016; 24:114.
Haas T, Fries D, Velik-Salchner C, Reif C, Kingler A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on Impaired clot formation after 60% dilution. Anesth Analg 2008; 106:1360–1365.
Hanna J, Winstedt D, Schochl U. Fibrinogen and FXIII dose response effect on albumin-induced coagulopathy. Scand J Clin Invest 2013; 73:553–562.
Winstedt D, Thomas OD, Nilsson F, Olanders K, Schott U. Correction of hypothermic and dilutional coagulopathy with concentrations of fibrinogen and factor XIII: an in vitro study with ROTEM. Scand J Trauma Resusc Emerg Med 2014; 22:73.
Tanaka KA, Taketomi T, Calatzis A, Levy JH. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettn P). Anesth Analg 2008; 106:732–738.
Sorensen B, Asvaldsdottir HS, Gudmundsdottir BR, Onudarson PT. The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery. Thromb Res 2009; 124:695–700.